Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis.
ÌÇÐÄ´«Ã½
Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis. Emerging infectious diseases Puing, A. G., Epstein, D. J., Banaei, N., Subramanian, A. K., Liu, A. Y. 2021; 27 (10): 2734-2736Abstract
Prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis developed, 16 subsequently tolerated TMP/SMX treatment. Clinicians should consider TMP/SMX allergy evaluation and rechallenging to assess patient tolerance.
View details for
View details for
View details for